Stock Research for NVS

Featured Broker: Ally Invest

Get the due diligence for another stock.


NVS Stock Chart & Research Data

The NVS chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the NVS chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


NVS Due diligence Resources & Stock Charts

The NVS stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View NVS Detailed Price Forecast - CNN Money CNN View NVS Detailed Summary - Google Finance
Yahoo View NVS Detailed Summary - Yahoo! Finance Zacks View NVS Stock Research & Analysis -

Stock Analysis

TradeIdeas View NVS Trends & Analysis - Trade-Ideas Barrons View NVS Major Holders - Barrons
NASDAQ View NVS Call Transcripts - NASDAQ Seeking View NVS Breaking News & Analysis - Seeking Alpha
Spotlight View NVS Annual Report - OTC Report View NVS OTC Short Report -
TradeKing View NVS Fundamentals - TradeKing Charts View NVS SEC Filings - Bar Chart
WSJ View Historical Prices for NVS - The WSJ Morningstar View Performance/Total Return for NVS - Morningstar
MarketWatch View the Analyst Estimates for NVS - MarketWatch CNBC View the Earnings History for NVS - CNBC
StockMarketWatch View the NVS Earnings - StockMarketWatch MacroAxis View NVS Buy or Sell Recommendations - MacroAxis
Bullish View the NVS Bullish Patterns - American Bulls Short Pains View NVS Short Pain Metrics -

Social Media Mentions

StockTwits View NVS Stock Mentions - StockTwits PennyStocks View NVS Stock Mentions - PennyStockTweets
Twitter View NVS Stock Mentions - Twitter Invest Hub View NVS Investment Forum News - Investor Hub
Yahoo View NVS Stock Mentions - Yahoo! Message Board Seeking Alpha View NVS Stock Mentions - Seeking Alpha

Financial & Transaction Holdings

SECform4 View Insider Transactions for NVS - Insider Cow View Insider Transactions for NVS - Insider Cow
CNBC View NVS Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for NVS - OTC Markets
Yahoo View Insider Transactions for NVS - Yahoo! Finance NASDAQ View Institutional Holdings for NVS - NASDAQ

Stock Charts

FinViz View NVS Stock Insight & Charts - StockCharts View NVS Investment Charts -
BarChart View NVS Stock Overview & Charts - BarChart Trading View View NVS User Generated Charts - Trading View

Latest Financial News for NVS

[$$] We Can’t Afford the Drugs That Could Cure Cancer
Posted on Friday September 21, 2018

When I was training as an oncologist nearly three decades ago, we dreamed of curing cancer. Today, advances in cellular immunotherapy make it no longer a dream: A cure for cancer has become possible, even probable. A potential revolution in cancer care may be stymied by the high price of drugs, which suggests that we need to reconsider how we price them.

NVS vs. AZN: Which Stock Is the Better Value Option?
Posted on Friday September 21, 2018

NVS vs. AZN: Which Stock Is the Better Value Option?

Should Value Investors Pick Novartis AG (NVS) Stock?
Posted on Friday September 21, 2018

Is Novartis AG (NVS) a great pick from the value investor's perspective right now? Read on to know more.

[$$] Triple Set of EMA Recommendations for Novartis Drugs
Posted on Friday September 21, 2018

AG (NOVN.EB) drugs and one Sandoz biosimilar have received a positive European Medicines Agency recommendation, the company and the regulator said in separate statements Friday. Novartis’ Gilenya, a multiple-sclerosis drug, received a positive recommendation for the treatment of children and adolescents with the condition. If approved, the drug would be the first oral disease-modifying therapy for these patients, Novartis said, adding that a full approval would expand the age-range of patients able to use the drug.

Stock Market & Investing Books

Enter a stock symbol to view the stock details.